Ultragenyx Pharmaceutical (RARE) incurred a second-quarter 2024 loss of $1.52 per share, narrower than the Zacks Consensus Estimate of a loss of $1.64. The company had reported a loss of $2.25 per share in the yearago quarter. Ultragenyx's total revenues amounted to $147 million in the reported quarter, up 36% year over year. The top line also beat the Zacks Consensus Estimate of $123 million on the back of higher product revenues. The company markets four drugs, namely Crysvita, Mepsevii, Dojolvi and Evkee ...